Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trialRichard Dodel, Frank Jessen, Peter Bartenstein et al.|The Lancet Neurology|2013Cited by 185
Mechanisms of action of naturally occurring antibodies against β-amyloid on microgliaMaike Gold, Jan‐Philipp Bach|Journal of Neuroinflammation|2013Cited by 29